TPP-1 TFA is a potent inhibitor of the PD-1/PD-L1 interaction. TPP-1 TFA binds specifically to PD-L1 with a high affinity (K_D=95 nM). TPP-1 TFA inhibits human tumor growth in vivo via reactivating T-cell function^[1].

TPP-1 TFA binds to PD-L1 with high affinity and blocks PD-1/PD-L1 interaction. The K_D value of PD-L1 with TPP-1 TFA peptide is about 95 nmol/L (around five times less than that with PD-1), The binding site of TPP-1 TFA to PD-L1 is close to the interactive site of PD-1 and PD-L1^[1].
TPP-1 TFA (4 μM) reactivates T-cell functions, it induces IFNγ release significantly higher than control and SPP-1, and the TPP-1 TFA group shows similar outcomes for cell proliferation^[1].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.

TPP-1 TFA (subcutaneous injection; 4 mg/kg; every other day eight times; 32 days) inhibits tumor growth (compared with SPP-1 and control). The growth rate in TPP-1 TFA-treated mice is 56%. And when administered in the absence of T cells (control group), TPP-1 TFA has no effect on the growth of the H460-luc tumors^[1].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.

2602.69

C₁₀₉H₁₅₁F₃N₃₄O₃₄S₂

SGQYASYHCWCWRDPGRSGGSK

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Chunlin Li, et al. Peptide Blocking of PD-1/PD-L1 Interaction for Cancer Immunotherapy. Cancer Immunol Res. 2018 Feb;6(2):178-188.